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ABSTRACT 
p300 is a Histone acetyltransferase which functions as global transcriptional 
coactivator which plays important roles in various biological processes including cell 
proliferation, differentiation, and apoptosis. As p300 is an acetyltransferase it stimulates 
many genes to express, thus carrying the process of transcription. So the aberrant activity 
of p300 may lead to many types of cancer. However, the mechanisms by which the 
inactivation of p300/CBP contributes to carcinogenesis have not been fully elucidated.  
  Normally, the expression of p300 should be remain at base levels in normal 
tissues. In cancer cells its expressions is expected to be higher as it is a transcriptional 
coactivator. The results obtained might be due to the activation of promoter regions of 
p300 by other epigenetic mechanisms (for example, demethylation of DNA by MBD 
proteins and GADD45 mediated mechanisms). 
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1. INTRODUCTION 
All organisms from lower invertebrates to higher vertebrates are made of cell. 
Cell is the structural and functional unit of all living organism. From the postulates of cell 
theory it was known that: new cell arise from pre-existing cell, all cells are chemically 
and physically similar, and finally function of an organism is governed by the sum total 
of activities and interactions of its constituent cells. Cell is a basic unit of life which 
exhibits a higher cellular organization in eukaryotes by containing different cell 
organelles. Nucleus is the most important and essential part of cell which directs and 
controls all the cellular activities and carries genetic information of cell. It contains 
component made of a long chain of nucleotide (pentose sugar, nitrogenous base, 
phosphate) called as nucleic acid i.e. DNA-the deoxyribonucleic acid. DNA is the basic 
thread of life which is transformed to RNA within the nucleus by the process of 
transcription. Again this RNA is transformed into protein in cytoplasm by the process 
called as translation. All these process whole together is called as central dogma. 
 
The amino acid sequence of every protein in a cell and the nucleotide sequence of 
every RNA is specified by a nucleotide sequence in a cell’s DNA. A segment of DNA 
molecule that contains the information required for the synthesis of a biological product, 
whether RNA or protein is referred to as a gene. A cell carries about 40,000 genes but 
only few of the genes have some housekeeping function by being suppressed or 
expressed. Eukaryotic DNA is packaged with proteins into sub-structures that are 
themselves packed into higher-order 30-nm fibers - the DNA-protein polymer called 
chromatin. Nucleosomes are the basic unit of DNA packaging in eukaryotes, consisting 
of a segment of DNA wound around a histone protein core. This structure is often 
compared to thread wrapped around a spool. The fundamental repeating unit in chromatin 
is the Nucleosome, which consists of 146 bp of DNA wrapped around an octamer of 
histone proteins. This core octamer contains two histone H2A, H2B dimers, and a histone 
H3-H4 tetramer .The compact architecture of chromatin naturally presents a significant 
barrier to all cellular events that require the underlying DNA and the accessibility of 
DNA is dynamically regulated through several distinct, but not mutually exclusive, 
mechanisms in order for transcription, DNA repair, replication and recombination to take 
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place. One of the most extensively studied mechanisms for altering chromatin structure is 
the post translational covalent modification of the histone amino-terminal tails. 
 
Chromatin assembly refers to the process in which histone H3/H4 tetramers and 
two H2A/H2B dimers are deposited sequentially onto newly synthesized DNA to form 
periodic arrays of Nucleosomes (Haushalter and Kadonaga et.al., 2003; Tyler et.al., 
2002). An extended definition includes chromatin condensation and the formation of 
higher-order structures, beyond which will be addressed here. Chromatin assembly is 
necessary for the replication of eukaryotic chromosomes (Haushalter and Kadonaga, 
2003). Factors involved in the chromatin assembly, or more strictly, Nucleosome 
assembly, include 2 histone chaperones (most of which are also known as chromatin 
assembly factors) and ATP-dependent chromatin assembly factors (Haushalter and 
Kadonaga, 2003; Tyler, 2002).  
 
Nucleosome assembly occurs in either DNA replication-dependent or independent 
manners (Haushalter and Kadonaga, 2003; Tyler, 2002). DNA replication dependent 
nucleosome assembly happens immediately after DNA replication or DNA repair during 
the cell cycle. Parental histones are randomly distributed to two daughter DNA strands at 
the replication fork, and the newly synthesized histones are deposited onto the remaining 
replicated DNA strands (Haushalter and Kadonaga, 2003; Krude and Keller, 2001; Mello 
and Almouzni, 2001; Tsurimoto, 1999; Tyler, 2002).  
 
In contrast, DNA replication independent nucleosome assembly occurs in 
differentiated cells that do not replicate (Ahmad and Henikoff, 2002; Ray-Gallet et al., 
2002; Wolffe and Hansen, 2001). Histone variants are thought to be involved in 
replication-independent nucleosome assembly pathway (Ahmad and Henikoff, 2002; 
Tagami et al., 2004). These histone variants, such as H2A.Z and H3.3, are synthesized 
outside of S phase and can be deposited onto DNA throughout the cell cycle (Haushalter 
and Kadonaga, 2003). DNA replication-independent nucleosome assembly has been 
proposed to provide a potential mechanism for histone turnover and therefore the switch 
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of epigenetic states (i.e. the modification marks on histones) (Bannister et.al., 2002; 
Haushalter and Kadonaga, 2003; Tagami et.al., 2004). 
 
1.1. EPIGENETICS: 
Epi-refers to “beside”, “upon” or “beyond” and genetics is the term that reflects 
the number and types of genes inherited, whereas epigenetics reflects the regulation of 
genes by chromatin modification. It refers to inheritable information that is encoded by a 
modification of genes and chromatin component. Epigenetic alterations in gene 
expression do not cause a change in the nucleotide sequence of DNA and are therefore 
not mutation. Epigenesis is the theoretical aspects of developmental biology and the 
strategy of genes was given by C.H.Waddinnton during 1930-1960.Epigenetic changes 
only influence the phenotype. There are two types of modifications related to epigenetics. 
They are: 
1) Histone modification  
2) DNA Methylation.  
Both can be acquired or inherited and both affect transcriptional activity by 
regulating the access of transcription factors to appropriate nucleotide sequence in gene 
promoters. 
 
Histone is a protein octamer containing two copies each of the histone proteins H2A 
(129 AA), H2B (125 AA), H3 (135 AA), and H4 (102 AA). H1 is the linker histone which 
binds two DNA outside the histone core. Each histone contains a domain for histone-histone 
and histone-DNA interaction and NH2-terminal Lysine rich and COOH–terminal tail domain 
which can be post-translationally modified. In biology, histones are highly 
alkaline proteins found in eukaryotic cell nuclei that package and order the DNA into 
structural units called nucleosomes. They are the chief protein components of chromatin, 
acting as spools around which DNA winds, and play a role in gene regulation. Without 
histones, the unwound DNA in chromosomes would be very long. For example, each human 
cell has about 1.8 meters of DNA, but wound on the histones it has about 90 millimeters (0.09 
m) of chromatin, which, when duplicated and condensed during mitosis, result in about 120 
micrometers of chromosomes. Histones "are highly conserved and can be grouped into five 
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major classes: H1/H5, H2A, H2B, H3, and H4". These are organized into two super-classes as 
follows: 
 core histones – H2A, H2B, H3 and H4 
 linker histones – H1 and H5 
 
Histone proteins are subject to a wide array of post-translational modifications 
including methylation, acetylation, phosphorylation, ubiquitination, and sumoylation 
occurring within the histone core region as well as on the N-terminal tails that protrude from 
the core region. 
 
1.2. CANCER AS EPIGENETIC DISEASE: 
Cancer is considered as an ensemble of diseases in part arising from chromosomal 
abnormalities and mutations in tumour-suppressor genes and oncogenes. Molecular and 
cellular mechanisms in malignant cell transformation increasingly indicate that cancer is also, 
in part, an epigenetic disease. The loss of DNA methylation at CpG dinucleotides in cancer 
cells was reported, and since this observation, the relations between cancer and DNA 
methylation were thoroughly studied. Epigenetics not only consists of DNA methylation, but 
also includes the other modifications of histones with a role in gene expression. Among 
histone modifications, methylation and deacetylation are the epigenetic processes more 
mechanistically linked to pathogenesis (Minucci S et.al., 2006)].  
 
Recent evidence indicates that their deregulation and mis-targeting contributes to the 
development of malignancies. Unfortunately, our knowledge of the behavior of histone 
modifications in cancer cells is limited, at least when compared with that of DNA 
methylation. It was shown that both acetylation and methylation participate in tumour-
suppressor genes silencing (Fahrner JA et.al., 2002). A deeper understanding of the epigenetic 
states in cancer cells is prompting investigators to integrate the different analyses aiming to 
identify the genetic determinants of epigenetic states (Laird PW et.al., 2005). 
 
Recently, novel studies on post-translational modifications of histones were reported 
characterizing the kind of modification occurring in normal tissues, cancer cell lines and in 
Role of p300 (HATs) in cancer Page 5 
 
primary tumours. The final goal of this approach is the identification of common hallmarks of 
human tumour cells in order to define unambiguous tools for cancer diagnostics and efficient 
drug therapies (Fraga MF et.al., 2005). 
 
1.3. HISTONE MODIFICATION 
Histone modification patterns are obviously not identical among different types of 
cancers and even subsequent stages of cancer display differently modified histone tails. Thus, 
classifying tumour types into specific epigenetic patterns could help in distinguishing them 
(Yoo CB et.al., 2006). The next and important task in tumour science is to understand how 
histone modifying complexes are involved in epigenetic modifications and how chromatin 
remodeling complexes are affected (Toyota M et.al., 2006).Histone modifications are of 
following types such as: 
 
1.3. a. ACETYLATION: 
The transfer of acetyl group from its cofactor acetyl co enzyme to the amino acids of 
the histone proteins is called as acetylation. This process is carried out by acetyl transferases. 
Histone acetylation generally makes chromatin accessible to the transcription-activating 
machinery, resulting in gene expression. One exception, the acetylation of histone H4 at 
lysine 12, has been found in regions of silent heterochromatin; therefore histone acetylation is 
not always associated with active transcription [Ballestar E, Paz MF, Valle L, et al 2003]. 
Overall, the acetylation state of histones seems to regulate the interconversion of active and 
repressive chromatin structure, but the molecular mechanism underlying the effects of histone 
acetylation on the state of chromatin is still poorly understood. Acetylation of histones 
neutralizes the positively charged lysine residues of the histone N-termini, which decreases 
their affinity for DNA. This results in unfolding of nucleosomes and increases access for 
transcription factors.  
Acetylation occurs in the following position of histone: 
H3- Acetylation occurs in 14, 9, 18 and13
th
 position of lysine 
H4- Acetylation occurs in 5, 8, 12, 16
th
 position of lysine 
H2A- Acetylation occurs in 5 and 9
th 
position of lysine 
H2B- Acetylation occurs in 5, 12, 15 and 20
th
 position of lysine. 
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1.3. b. METHYLATION: 
The transfer of methyl group from its cofactor SAM (S Adenosyl Methionone) to the 
amino acids basically arginine and lysine of histone protein is called as Methylation. 
Methylation occurs in two levels i.e. DNA level and histone level and therefore called as 
DNA Methylation and Histone Methylation. The enzymes involved in DNA Methylation are 
DNMT (DNA Methyl Transferase) and histone Methylation is HMT (Histone Methyl 
Transferase). Methylation works as gene silencing as a result of which they repress the 
transcription process. Methylation is further of two types i.e. genome wise hypomethylation 
and region wise Hypermethylation. 
 
Ways to repress a gene: 
 Competitive DNA binding 
 Masking the activation surface 
 Direct interaction with general transcription factors 
 Recruitment of repressive chromatin modeling complex 
 Remodeling of histone acetylases 
 
1.3. c. PHOSPHORYLATION: 
It’s a process which phosphorylates the molecule by adding phosphate group to the 
molecule by the help of the cofactor ATP. 
 
1.4. HISTONE ACETYL TRANSFERASE: 
Acetyltransferases are enzymes that catalyses the transfer of acetyl groups from acetyl 
coenzyme A to either the α- amino group of N-terminal amino acids or the ε- amino group of 
internal lysine residues. N terminal acetylation occurs during translation in the majority of 
eukaryotic proteins. In the reaction, acetyl coenzyme A serves as the acetyl group donor, and 
the final products are acetyl-lysine and CoA. Since cloning of the first histone 
acetyltransferases 10 years ago (Brownell et al.,1996; Kleff et.al., 1995; Parthun et.al., 1996), 
extensive studies have characterized their biological functions, mainly in budding yeast, fruit 
fly, and mammalian cells. It has become clear that HATs participate in most.  
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The phenomenon of histone acetylation in the eukaryotic cell has been known for 
many years, and since the early 1970s various HAT activities have been isolated and partially 
characterized. Each of these enzymes generally belongs to one of two categories: type A, 
located in the nucleus, or type B, located in the cytoplasm, although recent evidence indicates 
that some HAT proteins may function in multiple complexes or locations and thus not 
precisely fit these historical classifications . B-type HATs are believed to have somewhat of a 
housekeeping role in the cell, acetylating newly synthesized free histones in the cytoplasm for 
transport into the nucleus, where they may be deacetylated and incorporated into chromatin . 
The A-type HATs, on the other hand, acetylates nucleosome histones within chromatin in the 
nucleus; these HATs are potentially linked to transcription and thus are of main focus. 
 
1.4. a. STRUCTURE OF ACETYL TRANSFERASES 
Acetyltransferases are enzymes that catalyze the transfer of acetyl groups from acetyl 
coenzyme A to either the α- amino group of N-terminal amino acids or the ε- amino group of 
internal lysine residues. N terminal acetylation occurs during translation in the majority of 
eukaryotic proteins. In the reaction, acetyl coenzyme A serves as the acetyl group donor, and 
the final products are acetyl-lysine and CoA. 
 The introduction of an acetyl group into a molecule is called acetylation. Acetyl-CoA 
is an intermediate both in the biological synthesis and in the breakdown of many organic 
molecules. Histones and other proteins are often modified by acetylation .On the DNA level, 
histone acetylation by acetyltransferases (HATs) causes an expansion of chromatin 
architecture, allowing for genetic transcription to occur. However, removal of the acetyl group 
by histone deacetylases (HDACs) condenses DNA structure, thereby preventing transcription.  
 
1.4. b. HAT FAMILY 
The human genome contains about 30 histone acetyltransferases. However, it should 
be noted that HAT might be a misnomer in some cases. Many HATs have been shown to 
acetylate also non-histone targets, and some of them might not acetylate histones at all in 
more physiological conditions (Roth et.al., 2001). A number of acetylated non-histone 
proteins, such as transcription factors, importins, and tubulin, have been characterized in 
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recent years (Roth et.al., 2001). It is conceivable that acetylation also participates in, for 
example, signal transduction – perhaps it does not have as pervasive a role as protein kinases 
do, but nevertheless a substantial one (Kouzarides, 2000). 
 
 
Fig:1 Shows the recruitment of HAT and HDAC leading to transcription and repression 
(C.David Allis) 
 
Heterochromatin: The condensed or compact state of chromatin is known as 
heterochromatin. Here transcription process is suppressed or blocked. 
 
Euchromatin: The relaxed state of chromatin is known as euchromatin. Here transcription 
process is activated. 
Defects in H3 and H4 modification can have important implication in development of 
various cancers because the normal or correct regulation of heterochromatin and euchromatin 
is disrupted. Regions of heterochromatin becomes demethylated and converted to euchromatin 
as a result of which transcription is activated whereas regions of euchromatin becomes 
methylated and converted to heterochromatin as a result of which transcription is repressed. 
 
There are two main super families of HATs which have been well understood and 
characterized. They are GNAT (Gcn5-related N-Acetyltransferase) and MYST (MOZ, Ybf2-
Sas3, Sas2 and Tip60) families. The best-understood set of acetyltransferases is the GNAT 
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(Gcn5-related N-acetyltransferase) super families (174), which have been grouped together on 
the basis of their similarity in several homology regions and acetylation-related motifs. MYST 
family members function in a broad range of biological processes, such as gene regulation, 
dosage compensation, DNA damage repair and tumorigenesis (Utley & Cote, 2003). Although 
MYST proteins seem to have diverse cellular roles, all family members are characterized by 
the highly conserved MYST acetyltransferase domain and most MYST enzymes exist as the 
catalytic subunits of multiprotein complexes. Histone acetylation is linked transcriptional 
activation and associated with euchromatin. In most cases Histone Acetylation enhances 
transcription while histone deacetylation represses transcription. 
 
HATs can also have auto regulatory functions. Thompson et.al. (2004) showed that 
p300 contains an unstructured loop that is highly acetylated in vitro and in vivo. Hyper 
acetylation of the loop enhances the HAT activity of p300 both in vivo and in vitro, 
suggesting that HATs may be regulated like some kinases with an auto inhibitory loop 
(Thompson et.al., 2004). 
 
After initial correlative observations (Allfrey et.al., 1964), the connection between 
gene activity and histone acetylation gained further support by experiments showing that 
known transcriptional co-activators had intrinsic HAT activity (Bannister and Kouzarides, 
1996; Brownell et.al., 1996; Mizzen et al., 1996; Ogryzko et al., 1996; Yang et.al., 1996). 
Consequently, acetylation of histone tails as a mechanism for transcriptional activation has 
become a paradigm in molecular biology, although some counterexamples show that a causal 
link from acetylation to gene activation is sometimes too simplified a model (Kurdistani et.al., 
2004; Wang et.al., 2002). 
 
In mammals, two related Gcn5 acetyltransferase subclasses were described: GCN5 and 
p300/CREB-binding protein-associated factor (PCAF). PCAF is also able to acetylate 
transcription related to non-histone proteins like TFIIE, TFIIF, MyoD, p53, HIV tat, HMGN2 
and HMGA1. p300/CBP is yet another family of HATs. Recombinant p300 and CBP 
acetylate the amino terminal tails of all four (Bannister AJ et.al., 1996; Shikama N et.al., 
1997) Like PCAF, p300/CBP is known to acetylate and regulate transcription-related proteins 
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other than histones (Sterner DE et.al., 2000). They are considered as global transcription co-
activators playing critical roles in different cellular processes: cell-cycle, differentiation, 
apoptosis (Glass CK et.al., 200) other acetyltransferases, whose function is conserved from 
yeast to human are: Hat1, Hat2 (histone acetyltransferases B) and Elp3. Yeast Hat1 and Hat2, 
acting on free non-nucleosomal histones, are potentially involved in the chromatin assembly 
process, perhaps at the replication forks or at silenced telomeres (Ruiz-Garcia AB et.al., 
1998). Hat1 was recently shown to be also involved in DNA double-strand break (DSB) 
repair, being directly recruited to sites of DNA damage. Elp3 is able to acetylate all four 
histones and, even though its gene is not essential, the importance 210 Verdone et.al. 
 
 
1.5. BIOLOGICAL FUNCTIONS OF HATS 
 
1.5. a. HISTONE ACETYLATION IN GENE REGULATION 
Initially, HATs were appreciated mostly as local regulators of gene expression, for 
several reasons. First identified HATs, such as Gcn5, CBP, and p300, were already previously 
characterized co-activators with a role in the regulation of a specific set of genes. Moreover, 
the purification of HAT complexes revealed that they did not contain DNA binding proteins, 
further supporting the notion that they act as co-activators. However, histone acetylation 
participates, perhaps surprisingly, both in genome-wide and gene-specific regulation. Despite 
very high basal level of histone acetylation in the cell, HATs can still function as gene-
specific activators. It is currently poorly understood why and how these roles are separated.  
 
Some experimental data suggest that basal acetylation acts as a balance, so that both 
gene repression and gene activation can be temporally and spatially regulated more accurately 
(Vogelauer et.al., 2000). Another possibility is that abundant histone modifications function 
as an exclusion mechanism by limiting the binding of promiscuous silencing-inducing factors 
(Deuring et.al., 2000; van Leeuwen and Gottschling, 2002). Pulse-chase labeling and kinetic 
analysis of acetylated histones in various organisms has suggested that there are two pools of 
acetylated histones (reviewed in Waterborg, 2002). It is possible that the slow turn over 
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fraction corresponds to global acetylation and the fraction28 with fast turnover to gene-
specific regulation. However, experiments have not directly addressed this issue. 
 
The role of global histone acetylation in mammals is not very well understood. 
Previous studies have not addressed the effect of individual HATs or HDACs on acetylation 
of specific residues in vivo. Most studies have been performed with histone deacetylase 
inhibitors, such as trichostatin (Taddei et.al., 2005). The inherent problem in the analysis of 
global acetylation with current HDAC inhibitors is their relative unspecificity. TSA inhibits 
many HDACs, which makes the dissection of the responsible molecules complicated. 
Additionally, as HDACs have many other cellular targets besides histones, it is not possible to 
exclude their effect. It should be noted, however, that TSA and other HDAC inhibitors have a 
surprisingly limited effect on gene expression profiles (Gius et.al., 2004; Glaser et al., 2003; 
Van Lint et al., 1996). 
 
1.5. b. DNA REPLICATION 
DNA replication initiates at elements called origins of replication that are distributed 
all over the genome. Higher eukaryotes do not seem to have clear cis-acting sequences 
directing replication initiation (Bell and Dutta, 2002). DNA replication presents another, 
unrelated challenge for histone acetylation. During replication, new histones must be 
deposited on the newly synthesized DNA strands.  
 
There are two questions that emerge – how are the parental histones divided between 
daughter strands, and how can the established modification patterns be maintained through 
DNA replication? The latter is a fundamental question in epigenetics. The simplest way to 
preserve the epigenetic patterns would be semiconservative replication, where histone 
octamers are split during replication and each daughter strand inherits half of the old octamer, 
followed by restoration of the original pattern by maintenance methyl- and acetyltransferases. 
Although histones H3 and H4 form dimers during deposition (Tagami et al., 2004), most 
evidence suggests that replication is, nevertheless, conservative (Annunziato, 2005; Henikoff 
et.al., 2004). That is, the daughter strands inherit either the old tetramer or a newly 
synthesized one. One possibility is that the transcription machinery itself regulates G2 phase 
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histone modifications so that active genes re-establish correct histone modifications during 
next rounds of transcription (Henikoff et.al., 2004). Thus, transcription would feed back to 
histone modifications that were establishing the original transcriptional state. 
 
1.6. HISTONE ACETYLATION AND CANCER: 
Epigenetics-based mechanisms leading to carcinogenesis can be divided into three 
different categories: the first is the repression of normally active genes; the second is the 
activation of normally repressed genes; the last is the replacement of core histones by 
specifically modified histone variants. 
In the first two categories, abnormal activity of HATs and HDACs is involved, which 
seems to be either due to mutations of genes encoding for these enzymes or due to their 
binding and recruiting patterns. It was observed in tumours that a significant imbalance of 
acetylation and deacetylation levels takes place. Interestingly, the results are cell cycle arrest, 
re-differentiation or apoptosis. 
 
Histone acetylation plays many fundamental roles in cellular processes, one of them 
being crucial to cell proliferation. It is not surprising that mutations or chromosomal 
modifications involving HATs result in the development of malignancies. 
A characteristic feature of human leukemia is the presence of chromosomal 
translocations leading to the expression of fusion proteins, whose effects can be dual. Several 
translocations can inactivate the wild-type function of HATs causing the silencing of genes 
regulated by these enzymes. On the other hand, fusion proteins can derive from a HAT and a 
DNA-binding protein which can activate genes usually not expressed. This is the case of the 
acute myeloid leukemia (AML) in which a fusion between CBP and alternatively MOZ or 
mixed lineage leukemia (MLL) has occurred. The resulting protein also acquires a new 
function since it can add acetyl groups to different substrates. 
 
In a recent comparative analysis of normal cells, primary tumours and cancer cell 
lines, an altered recruitment of the acetyltransferases MOZ, MOF and MORF was found in 
cancer cell lines and this correlates with a global loss of the otherwise normally acetylated 
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H4-K16. This last feature was shown to be a common hallmark of human cancer and is 
usually accompanied by trimethylation at H4-K20. 
 
In addition, mutations of certain HATs also cause cancer, as observed in mice and in 
several cases of human leukemia. A biallelic mutation of the p300 locus was identified in 
human epithelial cancer. Another important disease in which HATs are not normal is the 
congenital Rubistein–Taybi syndrome where monoallelic mutations of both p300 and CBP 
increase susceptibility to cancer. The transcriptional coactivator p300/CBP (CREBBP) is a 
histone acetyltransferase (HAT) that regulates gene expression by acetylating histones and 
other transcription factors. Dysregulation of p300/CBP HAT activity contributes to various 
diseases including cancer1–4. Sequence alignments, enzymology experiments and inhibitor 
studies on p300/CBP have led to ontradictory results about its catalytic mechanism and its 
structural relation to the Gcn5.Several disease-associated mutations can also be readily 
accounted for by the p300 HAT structure. These studies pave the way for new epigenetic 
therapies involving modulation of p300/CBP HAT activity. The p300/CBP protein contains 
several well-defined protein interaction domains as well as a centrally located 380-residue 
HAT domain. To obtain direct information on p300/CBP acetyltransferase structure, 
enzymatic mechanism and inhibition, we prepared homogeneous p300 HAT domain for high 
resolution X-ray structure determination. 
 
1.7. p300/CBP 
p300 is a nuclear protein which acts as a transcriptional coactivator, having intrinsic 
acetyltransferase activity and is closely related to cyclic AMP-responsive element binding 
protein (CREB)–binding protein. p300 and CREB binding protein are involved in a number of 
different pathways, which affect cell cycle control, apoptosis, differentiation, and 
proliferation. The transcriptional coactivator p300/CBP (CREBBP) is a histone 
acetyltransferase (HAT) that regulates gene expression by acetylating histones and other 
transcription factors. p300 was suggested to have a function in DNA repair based on its 
association with PCNA (Hasan et.al., 2001), a protein mediating nucleotide excision repair 
(NER). However, there is no evidence that this interaction modulates NER. Another HAT 
linked to NER is GCN5. It is the catalytic subunit of the TFTC complex (TBP-free TAFII 
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complex), which preferentially binds and acetylates nucleosomes that contain UV-damaged 
DNA (Brand et.al., 2001). Histone acetylation is also increased in HeLa cells and yeast cells 
upon UV irradiation (Brand et.al., 2001; Yu et.al., 2005), and gcn5 mutant yeast is sensitive 
to UV (Teng et.al., 2002). 
 
 
Fig: 2 The multistep model of transcription. 
 
 First, ATP-dependent remodeling complexes alter the structure of chromatin. Second, 
coactivator HATs facilitate the formation of enhanceosomes and permit the actions of 
mediator complexes. p300/CBP may facilitate the recruitment of the mediator complex to 
active sites of transcription. Mediator, in turn, regulates transcription through interactions with 
components of the basal transcription machinery. The dashed line indicates an unknown 
association with DNA. GTFs, general transcription factors (Ngan Vo et.al., 2001). 
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2. REVIEW OF LITERATURE 
Epigenetics-based mechanisms leading to carcinogenesis can be divided into three 
different categories. The first is the repression of normally active genes. The second is the 
activation of normally repressed genes. The last is the replacement of core histones by 
specifically modified histone variants. In the first two categories, abnormal activity of HATs 
and HDACs is involved, which seems to be either due to mutations of genes encoding for 
these enzymes or due to their binding and recruiting patterns.  
 
The transcriptional coactivator p300/CBP (CREBBP) is a histone acetyltransferase 
(HAT) that regulates gene expression by acetylating histones and other transcription factors. 
Deregulations of p300/CBP HAT activity contributes to various diseases including cancer.  
 
The role of p300/CBP in tumour suppression has been proposed based on the fact that 
these coactivators are targeted by viral oncoproteins and that mutation of p300/CBP 
associated with inactivation of second allele have been identified in certain type of carcinoma. 
p300/CBP activity can be under aberrant control in human disease, particularly in cancer, 
which may inactivate a p300/CBP tumour-suppressor-like activity. 
 
2.1. ROLE OF p300 
After going through a number of papers we found one thing common that p300/CBP is 
a globally a transcriptional coactivator. The transcriptional coactivator’s p300 and CBP are 
highly conserved paralogous proteins, first identified by their interactions with adenoviral 
E1A and CREB (cAMP response element binding protein) respectively (Chrivia et.al., 1993 ; 
Eckner et.al., 1994).  
 
 p300/CBP regulate gene expression through interactions with nuclear proteins and 
participate in a broad spectrum of biological activities, including cell cycle regulation, 
differentiation, apoptosis and the DNA damage response (Giordano and Avantaggiati, 
1999; Goodman and Smolik, 2000).  
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 Both genes are targeted in a range of cancers: truncating and point mutations in 
epithelial cancers, and translocations in leukemia’s. This has led to the suggestion that 
p300 and CBP may function as classical tumor suppressor genes (Gayther et.al., 
2000; Ozdag et.al., 2002; Iyer et.al., 2004b; Ward et.al., 2005). 
 
 p300 and CBP function as prototype histone and factor acetyltransferases (HAT and 
FAT) by catalyzing the addition of an acetyl group to specific lysine residues on 
histones and other proteins, including p53, retinoblastoma (RB) and E2F (Gu and 
Roeder, 1997; Liu et.al., 1999; Martinez-Balbas et.al., 2000; Chan et.al., 2001). 
  
 Early experiments have suggested that the two homologs play interchangeable, 
apparently redundant roles in cell physiology. However, it is becoming increasingly 
clear that p300 and CBP have distinct, non overlapping functions in several pathways, 
such as the p53 response (Grossman, 2001; Iyer et.al., 2004a).                                                                                                  
 
 Histone acetyltransferase p300 functions as a transcriptional co-activator which 
interacts with a number of transcription factors. Monocytic leukemia zinc finger 
protein (MOZ) has histone acetyltransferase activity. It has been reported that the 
fusion of the MOZ gene to the p300 gene in acute myeloid leukemia with 
translocation (Kitabayashi et.al., 2001). The level and state of histone acetylation are 
regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs).  
 
 Some HATs and HDACs interact with specific DNA-binding transcription activator 
and repressor proteins, which strongly suggest that they modulate transcriptional 
activity of specific promoters by regulating local histone acetylation (Struhl K et.al., 
1998).  
 
 p300 and CREB-binding protein (CBP) were initially identified as cellular proteins 
which bind to the adenovirus-E1a oncoprotein and transcription factor CREB, 
respectively. p300/CBP are functionally conserved transcriptional coactivators for a 
large number of transcription factors and have intrinsic acetyltransferase activity. 
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 Deregulation of p300/CBP HAT activity contributes to various diseases including 
cancer. The p300/CBP protein contains several well-defined protein interaction 
domains as well as a centrally located 380-residue HAT domain (Fig. 1). To obtain 
direct information on p300/CBP acetyltransferase structure, enzymatic mechanism 
and inhibition, we prepared homogeneous p300 HAT domain for high-resolution X-
ray structure determination.  
 
 The role of the transcriptional coactivator p300 in cell cycle control was not analyzed 
till then due to the lack of appropriate experimental systems. The research group has 
examined cell cycle progression of p300-deficient cancer cell lines, where p300 was 
disrupted either by gene targeting (p300 cells) or knocked down using RNAi. Despite 
significant proliferation defects under normal growth conditions, p300-deficient cells 
progressed rapidly through G1 with premature S-phase entry.  
 
 Accelerated G1/S transition was associated with early retinoblastoma (RB) 
hyperphosphorylation and activation of E2F targets. The p300-acetylase activity was 
dispensable since expression of a HAT-deficient p300 mutant reversed these changes. 
In vitro kinase assays showed that p300 directly inhibits cdk6-mediated RB 
phosphorylation, suggesting p300 acts in early G1 to prevent Rb 
hyperphosphorylation and delay premature S-phase entry. These results suggest that 
p300 has an important role in G1/S control, possibly by modulating Rb 
phosphorylation. Stable over expression of p300 in fibroblasts delays S-phase entry 
(Baluchamy et.al., 2003). It has been suggested that the G1/S transition is regulated 
through variable activation of c-myc and c-myc-dependent targets (Kolli et.al., 2001; 
Baluchamy et.al., 2003; Rajabi et.al., 2005). 
 
2.1. a. Loss of p300 results in a G1/S transition defect: 
One possible explanation for the abnormal cell cycle distribution in p300 cells is 
that G1 to S phase transition may have been deregulated. Early S-phase entry in p300-
deficient cells is associated with premature Rb phosphorylation. It had been noted that 
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lowering p300 levels in human mammary epithelial and fibroblast cell lines accelerated 
S-phase entry and early DNA replication (Kolli et.al., 2001). 
 
2.1. b. Early S phase entry in p300 deficient cells is associated with premature Rb 
phosphorylation  
To identify mechanisms responsible for the defect in p300-deficient cells, expression 
levels of proteins known to regulate G1/S transition (total Rb, phosphorylated-Rb, acetylated-
RB, cyclin A, cyclin D, cyclin E, mcm2, p21 and c-myc) were analysed in HCT116 and p300 
cells, after serum-depletion and release. 
 
2.1. c. p300 directly inhibits cdk6, and promotes cdk2-dependent Rb kinase activities  
The role of p300/CBP in tumour suppression has been proposed based on the fact that 
these coactivators are targeted by viral oncoproteins, and that mutations of p300/CBP 
associated with inactivation of the second allele have been identified in certain types of 
carcinoma. However mechanism by which the inactivation p300/CBP contributes to 
carcinogenesis have not been fully elucidated. So the research group of Tamaki Suganuma 
focused on the understanding of p300 function in tumour suppression, particularly with regard 
to its relationship with the TGFβ and also discussed the effects of p300 mutation on the p53 
and cell proliferation (tamaki et.al., 2008). 
 
A major advance in knowledge on tumour suppressor proteins was brought about by 
the finding that the retinoblastoma (Rb) and p53 tumour suppressor are target for the 
oncogenic proteins of DNA tumour viruses. Previous studies have demonstrated that the 
adenovirus E1A(early region 1A), SV40 large T antigen(LT), and human papilloma 
virus(HPV) E7 proteins form complexes with Rb. Likewise, SV40 LT, adenovirus E1B, and 
E7 bind to p53. The interactions are dependent on domains in these viral oncoproteins 
important for their oncogeneic activities (Tamaki et.al., 2008). 
 
2.2. MUTATION OF p300/CBP GENES IN HUMAN CANCER: 
Direct evidence demonstrating a role for p300 in human tumours was lacking until the 
recently publication by Gayther et.al, which strongly supports a role for p300 as a tumour 
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suppressor. The authors identify truncating mutations associated with the loss or mutation of 
the second allele in both tumour samples and cell lines, suggesting that loss of p300 may play 
a role in the development of a subset of human cancers. The first suggestion that p300 and 
CBP may regulate growth and function as tumour suppressors was provided by studies of 
adenovirus E1A’s transforming properties. (Andrew C Phillips and Karen H Vousden 2000). 
 
The next important question to be addressed is how p300 mediates its tumour 
suppressive properties. One attractive hypothesis would be that, since p300 is involved in 
enhancing the transcriptional activity of p53 [Gu W, et.al., 1997], loss of its function would 
impair the ability of p53 to function as a tumour suppressor. 
 
Gayther et.al., strongly support a role for p300 as a tumour suppressor, and reveal an 
interesting dual role for CBP/p300 in the development of human cancer. In addition to 
functioning as tumour suppressors, both CBP and p300 can, in certain leukaemia strains, be 
oncogenic as a result of fusion to other proteins [Jacobson S, et.al., 1999, Borrow J 
et.al.,1998]. 
 
2.3. Involvement of CBP/p300 in cell growth and transformation: p300/CBP as tumor 
suppressors 
CBP and p300 participate in various tumor-suppressor pathways and these 
coactivators are essential for the actions of many oncogenes. Whether CBP and p300 promote 
apoptosis or cell proliferation appears to be highly context dependent. (Richard H. 
Goodman).Several characteristics of p300 and CBP suggested that these proteins might serve 
as tumor suppressors, but clear evidence for this function awaited the studies of Kung et.al. 
(2000). 
 
Muroaka et.al., (1996) identified p300 missense mutations associated with loss of 
heterozygosity in tumors from two patients, one with colorectal and the other with gastric 
carcinoma, and Gayther et al. (2000) recently reported five additional examples. 
 
Role of p300 (HATs) in cancer Page 20 
 
The growth suppression functions of p300 and CBP are also exemplified by their 
interactions with the tumor suppressor p53. Most of the critical functions of p53 are believed 
to occur through its ability to activate genes involved in the response to DNA damage, such as 
murine double minute (mdm-2), p21, cyclin G, and bax. Studies from different literature have 
shown that p53 interacts with a carboxy terminal region of p300/CBP and this interaction 
activation the transcription of the p53-responsive mdm-2, p21, and bax promoters 
(Avantaggiati et.al,. 1997; Gu et al. 1997; Lill et.al., 1997).  
 
As adenovirus E1A blocks p300/CBP function (Fig.3), it has been suggested that at 
least some of its effects on cell transformation might occur by inhibiting the actions of p53. 
Conversely, the growth suppression activities of p300 and CBP have been attributed to their 
ability to augment p53-mediated transcription. In addition to its transcriptional activation 
functions, p53 negatively regulates genes whose promoters do not contain a suitable binding 
site. Avanaggiati et.al., (1997) have suggested that the association of p53 and p300 might 
account for this effect, presumably by limiting access of the coactivator to promoter-bound 
transcription factors such as AP-1. 
 
Fig:3 Organization of CBP/p300- binding proteins. Association of CBP/p300 
with transcriptional activators (top) and basal transcription factors and HATs 
(bottom) is shown. The zinc fingers (Zn), CREB-binding domain (KIX), 
bromodomain (Bromo), HAT domain, and glutamine-rich domain (Q) are 
indicated. TBP, TATA-binding protein. 
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It has been describe that BRCA1-mediated transactivation is enhanced by 
p300/CBP (CREB binding protein) and that this effect was suppressed by the adenovirus 
E1A oncoprotein. BRCA1 is the first of the two identified familial breast cancer genes . 
p300/CBP Activates the Gal4-BRCA1 Carboxyl-Terminal Domain Transcription(Gerald 
M. Pao et.al.,1999). 
 
The human pituitary tumor transforming gene (hPTTG) serves as a marker for 
malignancy grading in several cancers. hPTTG is involved in multiple cellular pathways 
including cell transformation, apoptosis, DNA repair, genomic instability, mitotic control and 
angiogenesis induction. p300 increased the activity of hPTTG promoter/Luc. p300 induced the 
expression of hPTTG mRNA and protein. p300 enhanced the acetylation level of histone H3 at 
the hPTTG promoter. Histone deacetylation participated in the expression of hPTTG. ( Tian Li 
et.al., 2009). 
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3. OBJECTIVE 
p300 gene encodes a protein which causes histone acetyltransferase  activity and 
acts as a global transcriptional coactivator. This gene is found to be related in many of the 
cellular process whose abnormal activity leads to many cancers, including breast, 
colorectal, oral etc. It is a tumour suppressor gene which activates the activity of p53 
gene. From many experiments it was found that those cells or tissue having lack of p300 
is leading towards cancer. Many of the problems related to this were unsolved till now 
and because of this we focused particularly on p300 to know its expression and activity. 
Our major objective is to analyse the expression of p300 in normal tissue 
(blood) and various cancer tissue (Gall Bladder, Lymph Node etc). 
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4. MATERIALS AND METHODS 
 
SAMPLE COLLECTION 
 
The Human blood was collected from CWS Hospital, Rourkela as normal human 
tissue and Gall bladder and Lymph node cancer tissues were collected from Calcutta 
Medical College, Kolkata. 
 
4.1. Total RNA isolation 
 
Reagents and Buffers:- 
 TRIzol Reagents (Sigma), 
 Choloroform, 
 Isopropanol, 
 Ethanol (70%), 
 Denaturation Buffer 
 50 % deionized formamide, 
 2.2 M formaldehyde, 
 MOPS buffer (pH 7.0), 
 6.6 % glycerol, 
 0.5 % bromphenol,  
 Ethidium Bromide (EtBr), 
 Agarose 
 
 Protocol:- 
 50-100 mg of tissue in a 2 ml tube with 1 ml TRIzol was transferred. 
 Homogenized for 60 sec in the polytron. 
 200 l chloroform was added. 
 It was mixed by inverting the tube for 15 sec. 
 Incubated for 3 min at room temperature. 
 Centrifuged at 12.000 g for 15 min. 
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 The aqueous phase was transferred into a fresh Eppendorf tube. 
 500 l isopropanol was added. 
 Centrifuged at max. 12.000 g for 10 min in the cold room. 
 The pellet was washed with 500 l 70 % ethanol. 
 Centrifuged at max. 7.500 g for 5 min in the cold room. 
 The pellet was dried on air for 10 min. 
 Then the pellet was dissolved in 50-100 l DEPC-H2O. 
 Incubated for 10 min at 60 C. 
 Spectrophotometric reading was taken. 
 Analysed the RNA on a MOPS gel: 
 1-3 g RNA was dissolved in 11 l denaturation buffer. 
 1 l Ethidium bromide (1mg/ml) was added and denatured at 65 C for 15 min 
 1 % agarose gel was loaded in MOPS buffer plus 5 % formaldehyde. 
 The gel was run at 40 V for 4 h. 
 
4.2. cDNA synthesis (rt-PCR) 
 
Regents and Buffer:- 
 5X First Strand Buffer 
 10mM dNTP Set 
 0.1M DTT 
 Random Primers 
 RNase OUT Ribonuclease Inhibitor 
 Super Script II RNase H- Reverse Transcriptase 
 
Protocol:- 
 8µl of total RNA were taken. 
 Then 3 μl Random Primers was added. 
 1 μl dNTP mix was added. 
 Then vortex and spin downed tube. 
 Incubated at 65°C for 5 min. 
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 Placed tube on ice. 
 4 μl 5X Buffer, 2 μl DTT and 1μl RNAseOut were added. 
 Then vortex and spin downed tube. 
 Incubated at 42°C for 1 min. 
 1μl SuperScript II RNase H- Reverse Transcriptase was added. 
 Incubated at 42°C for 60 min. 
 Incubated at 70°C for 15 min. 
 180 μl of molecular grade water was added. 
 Nanodrop 1000 was used to measure concentration. Set sample typesetting to 
Other Sample and the constant to 33. 
 Stored at -80°C. 
 
GENE SPECIFIC PCR 
 
PRIMER USED 
 
 
Gene 
 
Forward 
 
Reverse   
p300 
 
5’ GACCCTCAGCTTTTAGGAATCC 3’ 
 
5’ TGCCGTAGCAACACAGTGTCT3’  
 
βactin 5’ TCTACAATGAGCTGCGTGTG 3’ 5’ ATCTCCTTCTGCATCCTGTC 3’ 
                                                                                                                    Kenji Suzuki.et.al., 2005 
  
   PCR Mixture:- (Total 25µl) 
 0.2 µM dNTP- 0.5µl 
 1.5 mM MgCl2- 1.5µl 
 1x PCR Buffer- 2.5µl 
 Taq Polymearse (5U/µl)- 0.5µl 
  Primers (0.2µM)- 0.5µl & 0.5µl 
 cDNA- 2µl 
 MQ Water- 17µl 
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    PCR Conditions:- 
                  
Event Temperature (
o
C) Time 
Denaturation 94 1 min 
2
nd
 Denaturation 94 20 sec 
Annealing 57 20 sec 
Extension 72 30 sec  
Final Extension 72 5 min 
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5. RESULTS  
 
Concentration and Purity of total extracted RNA:- 
   
Tissue Concentration.
 
(µg/ml) Purity 
260/280 260/230 
Blood 423.90 1.21 0.78 
Gall bladder 561.34 1.43 0.66 
Lymph node 833.35 1.79 1.2419 
 
 
Agarose gel electrophoresis analysis of RNA: 
 
 
 
 
 
 
 
 
 
 
             [ RNA in 1% agarose gel ]                         [Total RNA in denaturation gel]  
 
 
 
 
         1          2 
                                       Lane.1: Lymph Node Cancer 
                                                        Lane.2: Gall Bladder Cancer         
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Concentration of cDNA after PCR 
 
Genes Conc
n
.
 
(µg/ml) 
Blood Gall bladder Lymph node 
p300 1504.90 1495.05 1864.0 
β- Actin 2001.55 1834.67 1998.34 
 
 
 
 
Purity of c DNA after PCR at 260/280 
 
 
Genes Blood Gall bladder Lymph node 
p300 0.999 1.031 1.022 
β- Actin 1.001 1.012 1.331 
 
 
 
 
Purity of c DNA after PCR at 260/230 
 
 
Genes Blood Gall bladder Lymph node 
p300 0.968 1.012 1.2419 
β- Actin 1.001 1.008 1.0145 
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6. DISCUSSION 
From the experiments we have done in our laboratory it was observed that p300 
was highly expressed in lymph node cancer tissue as compared with the normal blood 
tissue and gall bladder cancer tissue.  Normally, the expression of p300 should be remain 
at base levels in normal tissues. In cancer cells its expressions is expected to be higher as 
it is a transcriptional coactivator. The results obtained might be due to the activation of 
promoter regions of p300 by other epigenetic mechanisms (for example, demethylation of 
DNA by MBD proteins and GADD45 mediated mechanisms). 
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